·The Hindu·15 marks·250–350 words

Concealing an adverse event in clinical research is a failure of both individual and institutional ethics. Examine with reference to a recent case.

New · District CollectorCan you hold the district for 72 hours?Floods, a heatwave, an outbreak, a grievance queue. Take the decisions, see the consequences.Play →
In this answer
  1. Individual ethical failure
  2. Institutional ethical failure
  3. Lessons for India

An adverse event is any death or serious harm to a trial participant. Reporting it honestly is the basis of trust in science. In 2025 a six-year-old girl with Snijders Blok-Campeau syndrome, a rare condition that does not threaten life, died after experimental gene therapy in Shanghai. The trial's lead scientist, Zilong Qiu, left her out of a February 2026 Nature paper [1]. The case shows that both individuals and institutions failed.

Individual ethical failure

  • Honesty and transparency: Leaving out a death distorts the scientific record and misleads other researchers and future patients [1].
  • Non-maleficence and risk-benefit: A risky therapy was given to a minor, who cannot consent, for a condition that was not life-threatening [1].
  • Accountability: Qiu was dismissed, barred from scientific projects for five years and listed for "serious breaches of research integrity" [1].

Institutional ethical failure

  • Ethics review lapse: Staff linked to the hospital were also punished. This means the trial's oversight failed, not just one person [1].
  • Detection failure: Peer review only sees what authors submit. The concealment was exposed by a Science–Retraction Watch investigation in July 2026, not by regulators [1].
  • Reactive enforcement: The penalties were administrative and came after the harm. They punish misconduct but do not protect the next patient [1].
  • Global governance gap: WHO's 2021 recommendations on human genome editing call for a registry and for ways to report unsafe research [2]. These safeguards were clearly missing here.

Lessons for India

  • India's first home-grown CRISPR therapy, BIRSA-101 for sickle cell disease, is moving towards patients. It will fall under the NDCT Rules, 2019 and the 2019 gene-therapy guidelines [3].
  • The Parliamentary Standing Committee on Health has recommended specialist and scientific review cadres in CDSCO [4].
  • Other steps: compulsory trial registration, serious adverse event reporting made a condition of grants, and whistleblower channels in hospitals.

Qiu's case shows that personal dishonesty can only succeed where oversight systems are weak. Safeguards should act before harm is done, through registries, specialist regulators and a culture of open reporting, rather than only punishing afterwards. This would protect the dignity of participants under Article 21 and build trust in innovation under SDG 3.

Sources

  1. 1Chinese scientist fired after child death in gene-editing trial: state media — The Hindu (AFP), Nov 2026the case facts, the *Nature* omission, the Science–Retraction Watch exposé, the sanctions and the hospital staff punished
  2. 2WHO issues new recommendations on human genome editing for the advancement of public health (12 July 2021)the registry, the reporting of unsafe research and the nine recommendation areas
  3. 3PIB — Parliament Question: Self reliance in CRISPR and gene editingBIRSA-101, the NDCT Rules 2019 and the 2019 gene-therapy guidelines
  4. 4PIB — Press Release on the 175th, 176th and 177th Reports of the Parliamentary Standing Committee on Health & Family Welfarespecialist and scientific review cadres for CDSCO

More from this note